New therapies to tackle type -2 diabetes is always a big industry. This week's NEJM publishes a clinical trial using a Interleukin-1 antagonist to improve glycaemic control in DM. Insulin production is increased, beta cell secretory functions are improved and there are very few side effects provided you were willing to inject the drug every day for 13 weeks. Hopefully, further studies might improve the dosing characteristics and lengthen the half life of the drug. If you are a diabetic and wait for a few more years, you might not have to inject insulin anymore, just a IL-1 antagonist.
If you know of patients paying a lot of money in private hospitals after a heart attack to get an operation to put a stent into them,let them know that its not always necessary. More importantly, let the doctors know to have a look at this paper involving over 2000 patients with stable coronary artery disease where percutaneous coronary intervention(PCI) + medical therapy did not have any added benefit over treating such patients by optimal medical therapy alone.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment